A Novel Cyanine and Porphyrin Based Theranostic Nanoagent for Near-Infrared Fluorescence Imaging Guided Synergistic Phototherapy
- PMID: 31271133
- DOI: 10.1166/jbn.2017.2427
A Novel Cyanine and Porphyrin Based Theranostic Nanoagent for Near-Infrared Fluorescence Imaging Guided Synergistic Phototherapy
Abstract
Design and synthesis of multifunctional organic nanoparticles (NPs) for non-invasive diagnosis and phototherapy of cancer are widely acknowledged. However, limited drug loading of NPs are major limitations for attaining synergistic effect in most of the combination therapies. Herein, a novel cyanine-porphyrin combined NPs (PGL-DiR) was fabricated in a simple and inexpensive way for the treatment of prostate cancer. A most commonly used near-infrared fluorescent (NIRF) cyanine dye, DiR was chosen as a photothermal agent to encapsulate in a porphyrin grafted lipid (PGL) (PGL-DiR) NPs of average size 156.25±31.31 nm. Unlike conventional liposomes, the self-assembled PGL morphology revealed encapsulation efficiency of DiR higher than 98%. However, as observed in vitro, DiR loading contents could trigger obvious quenching of singlet oxygen (1O₂) by PGL thereby reducing the efficiency of PDT. Nevertheless, after successful photobleaching of DiR, as prepared PGL-DiR NP could facilitate enhanced synergistic photothermal and photodynamic (PTT-PDT) therapy both in vitro and in vivo. After intravenous administration of PGL-DiR NPs in a PC3 tumor xenograft mice, a high accumulation in tumor until 24 hrs was clearly evident via NIRF imaging. With the successive laser irradiation, these NPs effectively suppressed the tumor growth synergistically as PTT < PDT < PTT + PDT while compared to monotherapies such as PTT or PDT alone. These results demonstrated that as prepared PGL-NPs could serve as an excellent theranostic agent both in vitro and in vivo for combined therapy of prostate cancer.
Similar articles
-
Self-assembly of porphyrin-grafted lipid into nanoparticles encapsulating doxorubicin for synergistic chemo-photodynamic therapy and fluorescence imaging.Theranostics. 2018 Nov 3;8(19):5501-5518. doi: 10.7150/thno.27721. eCollection 2018. Theranostics. 2018. PMID: 30555560 Free PMC article.
-
Chemotherapeutic drug-photothermal agent co-self-assembling nanoparticles for near-infrared fluorescence and photoacoustic dual-modal imaging-guided chemo-photothermal synergistic therapy.J Control Release. 2017 Jul 28;258:95-107. doi: 10.1016/j.jconrel.2017.05.011. Epub 2017 May 10. J Control Release. 2017. PMID: 28501673
-
Self-assembled albumin nanoparticles for combination therapy in prostate cancer.Int J Nanomedicine. 2017 Oct 24;12:7777-7787. doi: 10.2147/IJN.S144634. eCollection 2017. Int J Nanomedicine. 2017. PMID: 29123392 Free PMC article.
-
Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging- Guided Photothermal and Photodynamic Therapy of Cancer.Curr Top Med Chem. 2017;17(16):1858-1871. doi: 10.2174/1568026617666161122120537. Curr Top Med Chem. 2017. PMID: 27875977 Review.
-
Recent Advances in Cyanine-Based Phototherapy Agents.Front Chem. 2021 Jun 24;9:707876. doi: 10.3389/fchem.2021.707876. eCollection 2021. Front Chem. 2021. PMID: 34249874 Free PMC article. Review.
Cited by
-
Versatile Design of Organic Polymeric Nanoparticles for Photodynamic Therapy of Prostate Cancer.ACS Mater Au. 2023 Nov 6;4(1):14-29. doi: 10.1021/acsmaterialsau.3c00060. eCollection 2024 Jan 10. ACS Mater Au. 2023. PMID: 38221923 Free PMC article. Review.
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
-
Bubble-Manipulated Local Drug Release from a Smart Thermosensitive Cerasome for Dual-Mode Imaging Guided Tumor Chemo-Photothermal Therapy.Theranostics. 2019 Oct 18;9(26):8138-8154. doi: 10.7150/thno.36762. eCollection 2019. Theranostics. 2019. PMID: 31754386 Free PMC article.
-
Cerasomes and Bicelles: Hybrid Bilayered Nanostructures With Silica-Like Surface in Cancer Theranostics.Front Chem. 2018 Apr 18;6:127. doi: 10.3389/fchem.2018.00127. eCollection 2018. Front Chem. 2018. PMID: 29721494 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Miscellaneous
